BiTEs that have specificity for the peptide-major histocompatibility complex class I (pMHCI) of the target cells and CD3 of T or natural killer cells represent a novel class of antibodies, with highly promising therapeutic modalities against cancers associated with the mutant p53[68], and these BiTEs are often referred to as T cell receptor (TCR)-mimic (TCRm) or TCR-like antibodies. The gene discussed is TP53; the disease is cancer.